MADRIGAL PHARMACEUTICALS, INC.
No enriched coverage for $MDGL in the last 7 days.
Sibold William John (President and CEO) sold 11,583 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $538.65 ($527.88–$546.38, $6.24M total) across 24 trades over 2026-09-09 to 2026-09-11 under a Rule 10b5-1 trading plan.
Kelley Shannon T (General Counsel) sold 664 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $514.97 ($0.34M total) on 2026-08-17.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors CONSHOHOCKEN, Pa., August 12, 2026 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steato
Recent MDGL coverage spans insider activity, corporate actions and financial news.
In the last 30 days, MDGL insiders filed 24 SEC Form 4 transactions — no purchases and 24 sales ($6.2M). The most active reporter was Sibold William John, President and CEO, with 24 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sell may pressure MDGL price short term.
Insider sale may signal negative sentiment, but the amount is modest relative to float.
Board expansion and director compensation are unlikely to change near-term fundamentals, but can modestly affect sentiment and governance expectations.
Upgrade suggests a valuation reset opportunity if delays are perceived as less severe than priced.
Upgrade can support biotech momentum, but the article lacks the specific new clinical or regulatory datapoint.
AlphAI scores every news story that mentions MDGL with an AI model for sentiment and relevance, and aggregates insider trades from MADRIGAL PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sibold William John (President and CEO) sold 11,583 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $538.65 ($527.88–$546.38, $6.24M total) across 24 trades over 2026-09-09 to 2026-09-11 under a Rule 10b5-1 trading plan.
1 min readKelley Shannon T (General Counsel) sold 664 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $514.97 ($0.34M total) on 2026-08-17.
1 min readMADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors CONSHOHOCKEN, Pa., August 12, 2026 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steato
2 min readDeutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.
3 min readA roundup of Tuesday Wall Street analyst actions included Deutsche Bank upgrading Palantir to Buy and keeping a $200 target, and Wells Fargo initiating APi Group at Overweight with a $53 target. Other calls covered CoreWeave, Micron, Walmart, Nike, Apple, and SK Hynix, with multiple price targets and rating changes ahead of earnings for some names.
6 min readMADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates • Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% • As of June 30, 2026, more than 49,000 patient
6 min readSibold William John (President and CEO) sold 2,500 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $547.30 ($542.75–$555.05, $1.37M total) across 10 trades on 2026-07-20.
2 min readMadrigal Pharmaceuticals (NASDAQ:MDGL) said it granted equity inducement awards on July 1, 2026 to seven new non-executive employees under its 2025 Inducement Plan. Awards total 604 options and 2,952 time-based RSUs; options exercise price is $514.39/share and vest quarterly after a 1-year cliff. RSUs vest in four annual installments.
2 min readSuzhou Ribo Life Science (06938.HK) and subsidiary Ribocure, with Madrigal Pharmaceuticals (NASDAQ: MDGL), said they reached the first candidate-drug nomination milestone in their siRNA partnership for metabolic dysfunction-associated steatohepatitis (MASH). The companies plan to start IND-enabling studies to support upcoming clinical trials, covering multiple preclinical assets.
3 min readMADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2617490d2_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 MADRIGAL PHARMACEUTICALS, INC. 2026 STOCK PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Madrigal Pharmaceuticals 2026 Stock Plan (as amended from time to time, the “ Plan ”). The pur
3 min read
